- Home
- PGC vs YMAB Comparison
PGC vs YMAB Comparison
Compare PGC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGC
- YMAB
- Stock Information
- Founded
- PGC 1921
- YMAB 2015
- Country
- PGC United States
- YMAB United States
- Employees
- PGC N/A
- YMAB N/A
- Industry
- PGC Commercial Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PGC Finance
- YMAB Health Care
- Exchange
- PGC Nasdaq
- YMAB Nasdaq
- Market Cap
- PGC 559.4M
- YMAB 482.4M
- IPO Year
- PGC N/A
- YMAB 2018
- Fundamental
- Price
- PGC $32.12
- YMAB $6.19
- Analyst Decision
- PGC Buy
- YMAB Strong Buy
- Analyst Count
- PGC 1
- YMAB 10
- Target Price
- PGC $44.00
- YMAB $21.10
- AVG Volume (30 Days)
- PGC 85.3K
- YMAB 417.3K
- Earning Date
- PGC 01-31-2025
- YMAB 02-27-2025
- Dividend Yield
- PGC 0.62%
- YMAB N/A
- EPS Growth
- PGC N/A
- YMAB N/A
- EPS
- PGC 1.82
- YMAB N/A
- Revenue
- PGC $209,728,000.00
- YMAB $84,553,000.00
- Revenue This Year
- PGC N/A
- YMAB $6.09
- Revenue Next Year
- PGC $20.06
- YMAB $19.62
- P/E Ratio
- PGC $17.65
- YMAB N/A
- Revenue Growth
- PGC N/A
- YMAB N/A
- 52 Week Low
- PGC $20.30
- YMAB $6.01
- 52 Week High
- PGC $37.88
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- PGC 48.14
- YMAB 19.68
- Support Level
- PGC $31.00
- YMAB $6.05
- Resistance Level
- PGC $32.68
- YMAB $6.81
- Average True Range (ATR)
- PGC 1.02
- YMAB 0.49
- MACD
- PGC 0.18
- YMAB -0.02
- Stochastic Oscillator
- PGC 85.71
- YMAB 6.90
About PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Peapack Private Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and internet banking services. Peapack Private includes asset management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.